Impact of adjuvant breast cancer chemotherapy on fatigue, other symptoms, and quality of life.

Katherine L. Byar, Ann Malone Berger, Suzanne L. Bakken, Melissa A. Cetak

Research output: Contribution to journalArticle

130 Citations (Scopus)

Abstract

PURPOSE/OBJECTIVES: To identify differences in fatigue, other physical symptoms, and psychological symptoms and their relationship to quality of life (QOL) during chemotherapy and as long as one year after. DESIGN: Longitudinal, descriptive design embedded in a pilot intervention study. SETTING: Midwestern urban oncology clinics and patient homes. SAMPLE: 25 Caucasian women, aged 40-65 years (-X = 54.3), with stage I or II breast cancer receiving doxorubicin-based chemotherapy. METHODS: The Piper Fatigue Scale, Hospital Anxiety and Depression Scale, Symptom Experience Scale, and Medical Outcomes Study Short-Form General Health Survey were completed before and after each treatment; 30, 60, and 90 days after the last treatment; and one year after the first treatment. MAIN RESEARCH VARIABLES: Fatigue, physical and psychological symptoms, and QOL. FINDINGS: Fatigue levels were moderately intense during treatments and decreased significantly over time. Sleep disturbances and pain were the most frequent, intense, and distressing other physical symptoms. Anxiety was highest at baseline, and depression was highest during the fourth chemotherapy treatment. Fatigue was correlated with other physical and psychological symptoms at some times during treatments and consistently following treatments. Higher fatigue was associated with lower QOL in several domains. CONCLUSIONS: Fatigue is associated with other physical and psychological symptoms that fluctuate during and after treatment. Higher fatigue compromises QOL. IMPLICATIONS FOR NURSING: Interventions targeting primary or cluster symptoms can reduce the impact of adjuvant chemotherapy on fatigue, other symptoms, and QOL.

Original languageEnglish (US)
Pages (from-to)E18-26
JournalOncology nursing forum
Volume33
Issue number1
DOIs
StatePublished - Jan 2006

Fingerprint

Fatigue
Quality of Life
Breast Neoplasms
Drug Therapy
Psychology
Therapeutics
Anxiety
Depression
Piper
Adjuvant Chemotherapy
Health Surveys
Doxorubicin
Sleep
Nursing
Outcome Assessment (Health Care)
Pain

ASJC Scopus subject areas

  • Oncology(nursing)

Cite this

Impact of adjuvant breast cancer chemotherapy on fatigue, other symptoms, and quality of life. / Byar, Katherine L.; Berger, Ann Malone; Bakken, Suzanne L.; Cetak, Melissa A.

In: Oncology nursing forum, Vol. 33, No. 1, 01.2006, p. E18-26.

Research output: Contribution to journalArticle

Byar, Katherine L. ; Berger, Ann Malone ; Bakken, Suzanne L. ; Cetak, Melissa A. / Impact of adjuvant breast cancer chemotherapy on fatigue, other symptoms, and quality of life. In: Oncology nursing forum. 2006 ; Vol. 33, No. 1. pp. E18-26.
@article{e7057aa99fdf4ac9823af2e4eb2a24a5,
title = "Impact of adjuvant breast cancer chemotherapy on fatigue, other symptoms, and quality of life.",
abstract = "PURPOSE/OBJECTIVES: To identify differences in fatigue, other physical symptoms, and psychological symptoms and their relationship to quality of life (QOL) during chemotherapy and as long as one year after. DESIGN: Longitudinal, descriptive design embedded in a pilot intervention study. SETTING: Midwestern urban oncology clinics and patient homes. SAMPLE: 25 Caucasian women, aged 40-65 years (-X = 54.3), with stage I or II breast cancer receiving doxorubicin-based chemotherapy. METHODS: The Piper Fatigue Scale, Hospital Anxiety and Depression Scale, Symptom Experience Scale, and Medical Outcomes Study Short-Form General Health Survey were completed before and after each treatment; 30, 60, and 90 days after the last treatment; and one year after the first treatment. MAIN RESEARCH VARIABLES: Fatigue, physical and psychological symptoms, and QOL. FINDINGS: Fatigue levels were moderately intense during treatments and decreased significantly over time. Sleep disturbances and pain were the most frequent, intense, and distressing other physical symptoms. Anxiety was highest at baseline, and depression was highest during the fourth chemotherapy treatment. Fatigue was correlated with other physical and psychological symptoms at some times during treatments and consistently following treatments. Higher fatigue was associated with lower QOL in several domains. CONCLUSIONS: Fatigue is associated with other physical and psychological symptoms that fluctuate during and after treatment. Higher fatigue compromises QOL. IMPLICATIONS FOR NURSING: Interventions targeting primary or cluster symptoms can reduce the impact of adjuvant chemotherapy on fatigue, other symptoms, and QOL.",
author = "Byar, {Katherine L.} and Berger, {Ann Malone} and Bakken, {Suzanne L.} and Cetak, {Melissa A.}",
year = "2006",
month = "1",
doi = "10.1188/06.ONF.E18-E26",
language = "English (US)",
volume = "33",
pages = "E18--26",
journal = "Oncology Nursing Forum",
issn = "0190-535X",
publisher = "Oncology Nursing Society",
number = "1",

}

TY - JOUR

T1 - Impact of adjuvant breast cancer chemotherapy on fatigue, other symptoms, and quality of life.

AU - Byar, Katherine L.

AU - Berger, Ann Malone

AU - Bakken, Suzanne L.

AU - Cetak, Melissa A.

PY - 2006/1

Y1 - 2006/1

N2 - PURPOSE/OBJECTIVES: To identify differences in fatigue, other physical symptoms, and psychological symptoms and their relationship to quality of life (QOL) during chemotherapy and as long as one year after. DESIGN: Longitudinal, descriptive design embedded in a pilot intervention study. SETTING: Midwestern urban oncology clinics and patient homes. SAMPLE: 25 Caucasian women, aged 40-65 years (-X = 54.3), with stage I or II breast cancer receiving doxorubicin-based chemotherapy. METHODS: The Piper Fatigue Scale, Hospital Anxiety and Depression Scale, Symptom Experience Scale, and Medical Outcomes Study Short-Form General Health Survey were completed before and after each treatment; 30, 60, and 90 days after the last treatment; and one year after the first treatment. MAIN RESEARCH VARIABLES: Fatigue, physical and psychological symptoms, and QOL. FINDINGS: Fatigue levels were moderately intense during treatments and decreased significantly over time. Sleep disturbances and pain were the most frequent, intense, and distressing other physical symptoms. Anxiety was highest at baseline, and depression was highest during the fourth chemotherapy treatment. Fatigue was correlated with other physical and psychological symptoms at some times during treatments and consistently following treatments. Higher fatigue was associated with lower QOL in several domains. CONCLUSIONS: Fatigue is associated with other physical and psychological symptoms that fluctuate during and after treatment. Higher fatigue compromises QOL. IMPLICATIONS FOR NURSING: Interventions targeting primary or cluster symptoms can reduce the impact of adjuvant chemotherapy on fatigue, other symptoms, and QOL.

AB - PURPOSE/OBJECTIVES: To identify differences in fatigue, other physical symptoms, and psychological symptoms and their relationship to quality of life (QOL) during chemotherapy and as long as one year after. DESIGN: Longitudinal, descriptive design embedded in a pilot intervention study. SETTING: Midwestern urban oncology clinics and patient homes. SAMPLE: 25 Caucasian women, aged 40-65 years (-X = 54.3), with stage I or II breast cancer receiving doxorubicin-based chemotherapy. METHODS: The Piper Fatigue Scale, Hospital Anxiety and Depression Scale, Symptom Experience Scale, and Medical Outcomes Study Short-Form General Health Survey were completed before and after each treatment; 30, 60, and 90 days after the last treatment; and one year after the first treatment. MAIN RESEARCH VARIABLES: Fatigue, physical and psychological symptoms, and QOL. FINDINGS: Fatigue levels were moderately intense during treatments and decreased significantly over time. Sleep disturbances and pain were the most frequent, intense, and distressing other physical symptoms. Anxiety was highest at baseline, and depression was highest during the fourth chemotherapy treatment. Fatigue was correlated with other physical and psychological symptoms at some times during treatments and consistently following treatments. Higher fatigue was associated with lower QOL in several domains. CONCLUSIONS: Fatigue is associated with other physical and psychological symptoms that fluctuate during and after treatment. Higher fatigue compromises QOL. IMPLICATIONS FOR NURSING: Interventions targeting primary or cluster symptoms can reduce the impact of adjuvant chemotherapy on fatigue, other symptoms, and QOL.

UR - http://www.scopus.com/inward/record.url?scp=33744968427&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33744968427&partnerID=8YFLogxK

U2 - 10.1188/06.ONF.E18-E26

DO - 10.1188/06.ONF.E18-E26

M3 - Article

C2 - 16470230

AN - SCOPUS:33744968427

VL - 33

SP - E18-26

JO - Oncology Nursing Forum

JF - Oncology Nursing Forum

SN - 0190-535X

IS - 1

ER -